DT402 not checked

Definium Therapeutics US, Inc. · MM402

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA”In the company’s words, NCT07303907 on ClinicalTrials.gov
Tested for
Autism Spectrum Disorder, ASD
Main trialPhase 2
“A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder”In the company’s words, NCT07303907 on ClinicalTrials.gov
Other names
MM402 · R-MDMA · MDMA

Other drugs for Autism Spectrum Disorder

All 10 drugs for Autism Spectrum Disorder

Coming up0

No dates coming up.

Changes2

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Completed 16 Sep 2026 A Phase 2A Trial of DT402 for Autism Spectrum Disorder
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow DT402

Following is part of Solo: you see every change to DT402 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in